Addex Therapeutics Business Summary

Addex Therapeutics Ltd. (ADXN) is a clinical-stage biopharmaceutical company specializing in the discovery and development of allosteric modulators for neurological disorders. The company generates revenue primarily through strategic research and development collaborations, licensing agreements, and non-dilutive grants, such as its long-standing partnership with Indivior for GABAB PAM and recent funding for its mGlu2 program. Operating as a single business segment focused on small-molecule pharmaceutical products, Addex leverages its proprietary discovery platform to target receptors like mGlu5, mGlu2, and GABAB for indications including epilepsy, chronic cough, and post-stroke recovery. In the competitive landscape of CNS-focused biotechnology, Addex competes with firms like AC Immune, Axsome Therapeutics, and Atara Biotherapeutics, positioning itself as a pioneer in the niche allosteric modulation space, which offers higher selectivity and reduced side-effect profiles compared to traditional orthosteric agonists. The leadership team is anchored by Co-Founder and CEO Tim Dyer, who brings over two decades of experience in corporate development and finance, including a ten-year tenure at PricewaterhouseCoopers (PwC). He is supported by Chief Medical Officer Dr. Roger Mills, an industry veteran with extensive experience in clinical drug development, and Mikhail Kalinichev, the Head of Translational Science, who oversees the transition of preclinical assets into human trials. The executive team is further bolstered by Lénaïc Teyssédou, Head of Finance, who manages the firm’s capital strategy and its 2024-2025 spin-out of Neurosterix. Notable institutional backing includes Roche, SR One, and TVM Capital, alongside Perceptive Advisors, which played a critical role in the $63 million financing of the Neurosterix venture to accelerate the company's M4 PAM schizophrenia program.